S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Buy THIS stock before Taiwan is attacked (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Buy THIS stock before Taiwan is attacked (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Get MarketBeat All Access Free for 30 Days (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Buy THIS stock before Taiwan is attacked (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Buy THIS stock before Taiwan is attacked (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Get MarketBeat All Access Free for 30 Days (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Buy THIS stock before Taiwan is attacked (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Buy THIS stock before Taiwan is attacked (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Get MarketBeat All Access Free for 30 Days (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
Buy THIS stock before Taiwan is attacked (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Buy THIS stock before Taiwan is attacked (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Get MarketBeat All Access Free for 30 Days (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?

Merrimack Pharmaceuticals (MACK) Stock Forecast, Price & News

$12.52
0.00 (0.00%)
(As of 05/31/2023 ET)
Compare
Today's Range
$12.40
$12.53
50-Day Range
$11.87
$13.07
52-Week Range
$3.00
$13.66
Volume
20,111 shs
Average Volume
108,520 shs
Market Capitalization
$178.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Merrimack Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
5.05% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.57mentions of Merrimack Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$1.85 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.71 out of 5 stars

Medical Sector

863rd out of 1,006 stocks

Pharmaceutical Preparations Industry

431st out of 492 stocks


MACK stock logo

About Merrimack Pharmaceuticals (NASDAQ:MACK) Stock

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MACK Stock News Headlines

Instantly Find Hidden Trade Opportunities
There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.
Instantly Find Hidden Trade Opportunities
There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.
Merrimack Valley High School
Merrimack Reports Full Year 2022 Financial Results
See More Headlines
Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MACK Company Calendar

Last Earnings
3/09/2023
Today
5/31/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MACK
CUSIP
59032810
Employees
426
Year Founded
2000

Profitability

Net Income
$-1,540,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.34 per share

Miscellaneous

Free Float
10,143,000
Market Cap
$178.54 million
Optionable
Optionable
Beta
1.84

Social Links


Key Executives

  • Mr. Gary L. Crocker M.B.A.Mr. Gary L. Crocker M.B.A. (Age 70)
    MBA, Pres, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman
    Comp: $105.44k
  • Dr. Ulrik B. Nielsen Ph.D. (Age 50)
    Co-Founder & Independent Director
    Comp: $102.76k
  • Dr. Anthony J. Sinskey Ph.D. (Age 82)
    Sc.D., Co-Founder and Scientific Advisor
  • Geoffrey Grande C.F.A.
    Sr. Director of Communications
  • Ms. Ellen K. Forest (Age 58)
    Head of HR
  • Dr. Fazal R. Khan Ph.D. (Age 72)
    Sr. VP of Manufacturing
  • Dr. Daryl C. Drummond Ph.D. (Age 53)
    Head of Research
  • Mr. Timothy R. Surgenor (Age 62)
    Sec.













MACK Stock - Frequently Asked Questions

How have MACK shares performed in 2023?

Merrimack Pharmaceuticals' stock was trading at $11.46 at the start of the year. Since then, MACK shares have increased by 9.2% and is now trading at $12.52.
View the best growth stocks for 2023 here
.

When is Merrimack Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our MACK earnings forecast
.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) posted its quarterly earnings data on Thursday, March, 9th. The biopharmaceutical company reported ($0.03) EPS for the quarter.

What ETFs hold Merrimack Pharmaceuticals' stock?

ETFs with the largest weight of Merrimack Pharmaceuticals (NASDAQ:MACK) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC),

When did Merrimack Pharmaceuticals' stock split?

Merrimack Pharmaceuticals's stock reverse split on the morning of Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Merrimack Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM).

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

Who are Merrimack Pharmaceuticals' major shareholders?

Merrimack Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Madison Avenue Partners LP (3.88%), Dimensional Fund Advisors LP (3.27%), Sio Capital Management LLC (1.91%), BlackRock Inc. (1.56%), Susquehanna International Group LLP (0.00%) and Wittenberg Investment Management Inc. (1.39%). Insiders that own company stock include Ana Radeljevic, Eric Andersen, Gary L Crocker, Noah G Levy and Ulrik B Nielsen.
View institutional ownership trends
.

How do I buy shares of Merrimack Pharmaceuticals?

Shares of MACK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merrimack Pharmaceuticals' stock price today?

One share of MACK stock can currently be purchased for approximately $12.52.

How much money does Merrimack Pharmaceuticals make?

Merrimack Pharmaceuticals (NASDAQ:MACK) has a market capitalization of $178.54 million. The biopharmaceutical company earns $-1,540,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis.

How many employees does Merrimack Pharmaceuticals have?

The company employs 426 workers across the globe.

How can I contact Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The official website for the company is www.merrimackpharma.com. The biopharmaceutical company can be reached via phone at 617-720-8606, via email at ir@merrimack.com, or via fax at 617-491-1386.

This page (NASDAQ:MACK) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -